(Q37203832)

English

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers

scientific article published on 05 July 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

influenza A virus

object named as

Influenza A Virus

1 reference

based on heuristic

inferred from title

7

object named as

Mauricio Maia

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

author name string

Jeremy J Lim

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rong Deng

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Michael A Derby

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Richard Larouche

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Priscilla Horn

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Malia Anderson

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Stephanie Carrier

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Isabelle Pelletier

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Tracy Burgess

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Priya Kulkarni

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Elizabeth Newton

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jorge A Tavel

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

5 July 2016

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

60

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

5437-5444

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Antibody-Based Strategies to Prevent and Treat Influenza

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Estimating influenza disease burden from population-based surveillance data in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Passive immunity in the prevention of rabies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

A guide to rational dosing of monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Monoclonal antibody-based therapies for microbial diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Therapeutic antibodies: successes, limitations and hopes for the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Progress towards recombinant anti-infective antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

The growth and potential of human antiviral monoclonal antibody therapeutics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Clinical uses of intravenous immunoglobulin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Passive antibody therapy for infectious diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

6 September 2017

Influenza-Related Hospitalizations and Poverty Levels - United States, 2010-2012.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

14 September 2017

Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

14 September 2017

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

14 September 2017

Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

26 June 2018

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

3 September 2018

Viral loads and duration of viral shedding in adult patients hospitalized with influenza.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4997859

3 September 2018

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://pubmed.ncbi.nlm.nih.gov/27381392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00607-16

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37203832&oldid=1802630530"